Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorEngelhardt, Britta
dc.contributor.authorComabella Lopez, Manuel
dc.contributor.authorChan, Andrew
dc.date.accessioned2022-09-07T11:51:38Z
dc.date.available2022-09-07T11:51:38Z
dc.date.issued2022-06
dc.identifier.citationEngelhardt B, Comabella M, Chan A. Multiple Sclerosis: Immunopathological heterogeneity and its implications. Eur J Immunol. 2022 Jun;52(6):869–81.
dc.identifier.issn1521-4141
dc.identifier.urihttp://hdl.handle.net/11351/8052
dc.descriptionBiomarkers; Brain barriers immunotherapy; Multiple sclerosis
dc.description.abstractMS is the most common autoimmune demyelinating disease of the CNS. For the past decades, several immunomodulatory disease-modifying treatments with multiple presumed mechanisms of action have been developed, but MS remains an incurable disease. Whereas high efficacy, at least in early disease, corroborates underlying immunopathophysiology, there is profound heterogeneity in clinical presentation as well as immunophenotypes that may also vary over time. In addition, functional plasticity in the immune system as well as in the inflamed CNS further contributes to disease heterogeneity. In this review, we will highlight immune-pathophysiological and associated clinical heterogeneity that may have an implication for more precise immunomodulatory therapeutic strategies in MS.
dc.language.isoeng
dc.publisherWiley
dc.relation.ispartofseriesEuropean Journal of Immunology;52(6)
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScientia
dc.subjectEsclerosi múltiple - Tractament
dc.subjectResposta immunitària - Regulació
dc.subjectMedicina personalitzada
dc.subject.meshMultiple Sclerosis
dc.subject.meshImmunomodulation
dc.subject.meshPrecision Medicine
dc.titleMultiple sclerosis: Immunopathological heterogeneity and its implications
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1002/eji.202149757
dc.subject.decsesclerosis múltiple
dc.subject.decsinmunomodulación
dc.subject.decsmedicina de precisión
dc.relation.publishversionhttps://doi.org/10.1002/eji.202149757
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Engelhardt B] Theodor Kocher Institute, University of Bern, Bern, Switzerland. [Comabella M] Servei de Neurologia-Neuroimmunologia, Centre d’Esclerosi Múltiple de Catalunya (CEMCAT), Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Chan A] Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. Department for BioMedical Research (DBMR), University of Bern, Bern, Switzerland
dc.identifier.pmid35476319
dc.identifier.wos000791546500001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record